泰格医药(300347) - 2024 Q3 - 季度财报

Financial Performance - Revenue for the third quarter was 1.709 billion yuan, a decrease of 11.87% year-over-year[2] - Net profit attributable to shareholders was 320.58 million yuan, down 34.74% year-over-year[2] - Total revenue for the current period is 5,067,615,359.89 yuan, compared to 5,650,477,938.01 yuan in the previous period, indicating a decrease[17] - Operating costs for the current period are 4,026,550,519.06 yuan, down from 4,142,186,555.14 yuan in the previous period[17] - Net profit attributable to the parent company is 9,096,932,877.14 yuan, compared to 8,774,794,749.44 yuan in the previous period[16] - Net profit attributable to parent company shareholders reached 813,428,915.46 yuan, a decrease compared to the previous period's 1,879,604,430.16 yuan[18] - Total comprehensive income for the period was 852,425,592.60 yuan, down from 2,094,817,707.62 yuan in the previous period[18] - Basic earnings per share were 0.94 yuan, compared to 2.17 yuan in the previous period[18] Cash Flow and Financial Position - Operating cash flow for the year-to-date was 578.77 million yuan, a decrease of 13.96% year-over-year[2] - Cash flow from operating activities was 578,769,609.95 yuan, a decrease from 672,644,481.56 yuan in the previous period[19] - Cash flow from investing activities showed a significant outflow of -5,723,116,899.53 yuan, compared to -1,592,504,848.56 yuan in the previous period[19] - Cash flow from financing activities was -272,001,685.95 yuan, a sharp decline from 474,861,241.52 yuan in the previous period[19] - Net cash and cash equivalents decreased by 5,438,054,513.77 yuan, compared to a decrease of 422,792,070.34 yuan in the previous period[19] - Cash and cash equivalents at the end of the period are 1,967,632,936.81 yuan, down from 7,419,991,842.25 yuan at the beginning of the period[14] Assets and Liabilities - Total assets increased by 2.01% to 30.277 billion yuan compared to the end of the previous year[2] - Total assets at the end of the period are 30,276,592,021.30 yuan, compared to 29,680,742,349.17 yuan at the beginning of the period[15] - Total liabilities at the end of the period are 5,857,792,870.10 yuan, up from 5,227,180,203.91 yuan at the beginning of the period[16] - Short-term borrowings at the end of the period are 3,010,434,835.00 yuan, up from 1,969,693,500.00 yuan at the beginning of the period[15] - Contract assets at the end of the period are 2,940,514,164.81 yuan, compared to 2,364,435,242.53 yuan at the beginning of the period[14] - Other non-current financial assets at the end of the period are 10,716,445,742.86 yuan, up from 10,231,701,776.67 yuan at the beginning of the period[15] - The company's short-term borrowings increased by 52.84% to 3.010 billion yuan[5] - Prepaid expenses increased by 110.53% to 119.05 million yuan due to increased prepayments for services[5] - The company's inventory stock decreased by 78.01% to 191.15 million yuan due to the cancellation of treasury shares[5] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 53,084[8] - Ye Xiaoping holds 20.49% of the shares, totaling 177,239,541 shares[8] - HKSCC NOMINEES LIMITED holds 14.23% of the shares, totaling 123,118,679 shares[8] - Cao Xiaochun holds 5.97% of the shares, totaling 51,661,774 shares[8] - The Industrial and Commercial Bank of China Limited - China Europe Medical Health Hybrid Securities Investment Fund holds 3.48% of the shares, totaling 30,077,282 shares[8] - Hong Kong Securities Clearing Company Limited holds 2.65% of the shares, totaling 22,936,271 shares[8] - The Bank of China Limited - Huabao CSI Medical ETF holds 2.08% of the shares, totaling 17,956,750 shares[8] - The Industrial and Commercial Bank of China Limited - E Fund ChiNext ETF holds 1.69% of the shares, totaling 14,631,783 shares[8] - Shi Xiaoli holds 1.16% of the shares, totaling 10,031,703 shares[8] - The Industrial and Commercial Bank of China Limited - Huatai-PineBridge CSI 300 ETF holds 1.16% of the shares, totaling 10,004,766 shares[8] Expenses and Income - The company's financial expenses increased by 129.66% to 31.37 million yuan due to reduced interest income and increased interest expenses[6] - Government subsidies received during the period amounted to 22.33 million yuan, contributing to other income[6] - R&D expenses for the current period are 172,098,760.28 yuan, a decrease from 195,343,150.53 yuan in the previous period[17] Investment Activities - Investment activities resulted in a cash outflow of 5.723 billion yuan, primarily due to the purchase of large-denomination certificates of deposit[7] Reporting and Audit - The company's third-quarter report was unaudited[20]